^
Association details:
| Biomarker: | PIK3R1 M326I |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | GSK2636771 (PI3Kβ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials.
Published date:
01/18/2022
Excerpt:
In patients treated with GSK2636771 and paclitaxel, patients with PIK3R1 M326I mutation (n = 3) showed longer PFS (8.1 vs 2.8 months, P= 0.041)...HLA genotyping were potential predictors of each targeted agent or immunotherapy as a 2nd line treatment of AGC patients, regardless of paclitaxel.
DOI:
10.1200/JCO.2022.40.4_suppl.351
Trial ID:
